Clinical trials: Neuroendocrine Tumor Metastatic
Melanoma (Skin)
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases).
- Trial name
- NCT05704647
- Testing
- BMS-986213 (Relatlimab-Nivolumab FDC), Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroendocrine Tumor
Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.
- Trial name
- NCT01099540
- Testing
- Pazopanib
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Samsung Medical Center
Uveal Melanoma
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Primary objective is to define the maximum tolerated dose (MTD) for the combination of AEB071 and BYL719. Secondary objectives are to define the safety and tolerability of AEB071 and BYL719.
- Trial name
- NCT02273219
- Testing
- AEB071, BYL719
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Columbia University
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Gastrointestinal Tumors, Pancreatic Tumors
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
The purpose of this study is to explore the efficacy and safety of everolimus administered as a first-line treatment in newly-diagnosed patients with advanced or inoperable Gastrointestinal (GI) or pancreatic neuroendocrine…
- Conditions
- Gastrointestinal Tumors, Pancreatic Tumors, Gastrointestinal Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors
- Trial name
- NCT01648465
- Testing
- Everolimus
- Where
- 12 sites in Greece
- Volunteers
- 25 people
- Sponsor
- Hellenic Cooperative Oncology Group
Melanoma Metastatic, NRAS Mutation
Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
This study evaluates the combination of the autophagy inhibitor hydroxychloroquine (HCQ), the MEK inhibitor tunlametinib, and the anti-PD-1 antibody pucotenlimab in patients with locally advanced or metastatic melanoma.
- Trial name
- NCT07750067
- Testing
- Tunlametinib, Pucotenlimab, Hydroxychloroquine (HC)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Melanoma, Renal Cell Carcinoma
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).
- Conditions
- Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced
- Trial name
- NCT04955743
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
The purpose of this study is to determine whether GSK1120212, a MEK inhibitor, is an effective and safe treatment for cancer subjects with metastatic uveal melanoma and mutation-positive GNAQ or GNA11 metastatic melanoma.
- Conditions
- GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma, Cancer, Metastatic Uveal Melanoma
- Trial name
- NCT01328106
- Testing
- GSK1120212
- Sponsor
- GlaxoSmithKline
Metastatic Melanoma, Unresectable Melanoma
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with…
- Conditions
- Metastatic Melanoma, Unresectable Melanoma, Melanoma
- Trial name
- NCT05727904
- Testing
- Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period
- Where
- 82 sites in United States, Australia and 14 more
- Volunteers
- 670 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Carcinoid Tumor, Metastatic Carcinoid Tumor
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies how well nintedanib works in treating patients with neuroendocrine tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or have spread from the primary…
- Conditions
- Carcinoid Tumor, Metastatic Carcinoid Tumor, Neuroendocrine Neoplasm
- Trial name
- NCT02399215
- Testing
- Laboratory Biomarker Analysis, Nintedanib, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Roswell Park Cancer Institute
Adrenocortical Carcinoma, Pheochromocytoma
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- Spencer (NCT04187404)
- Testing
- EO2401, Nivolumab
- Where
- 12 sites in United States, Denmark and 6 more
- Volunteers
- 70 people
- Sponsor
- Enterome
Metastatic, Uveal Melanoma
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Selumetinib therapy in patients with metastatic uveal melanoma.
- Trial name
- SUMIT (NCT01974752)
- Testing
- 75mg selumetinib, Dacarbazine
- Where
- 31 sites in United States, Belgium and 9 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Metastatic Malignant Melanoma
Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.
- Trial name
- NCT02617849
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Wilson Miller
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from a patient's white blood cells mixed with tumor antigens may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00017355
- Testing
- filgrastim, therapeutic autologous dendritic cells
- Where
- United States
- Sponsor
- Baylor Health Care System
Recurrent Melanoma, Recurrent Renal Cell Cancer
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of temsirolimus when given together with bryostatin 1 in treating patients with unresectable or metastatic solid tumors.
- Conditions
- Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage IV Melanoma, Stage IV Renal Cell Cancer
- Trial name
- NCT00112476
- Testing
- bryostatin 1, temsirolimus
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Metastatic Neuroendocrine Tumors
Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
The purpose of this study is to examine if PTK787/ZK222584 (vatalanib) will stabilize or decrease rising biochemical markers along with progressive disease or syndrome symptoms in patients with metastatic neuroendocrine tumors.
- Trial name
- PTK787 (NCT00590343)
- Testing
- vatalanib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Melanoma, In-Transit Metastasis of Cutaneous Melanoma
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
There is currently an urgent need for low cost and well tolerated intralesional agents for the management of in transit and cutaneous melanoma metastases that are unsuitable for, or resistant to, other therapies.
- Trial name
- INTRANS (NCT03754140)
- Testing
- Polidocanol Injection
- Where
- Australia
- Sponsor
- Melanoma Institute Australia
Metastatic Melanoma
A Phase I/II Study of Dasatinib and Dacarbazine
The purpose of this study is to: Phase I Objectives: Find the most tolerated dose to use for Phase II Collect information on how the body responds to this combination of study drug Phase II Objectives: To determine the overall…
- Trial name
- NCT00597038
- Testing
- Dasatinib and Dacarbazine (DTIC)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.